In December 2024, the adult sons of Marjorie Tingley received an urgent message from the dementia care unit at Vista Grande Villa, a senior living community in Michigan. Administrators warned that their 85-year-old mother had become a serious safety risk to staff and others around her.
According to behavior logs kept by the facility, Tingley had struck, kicked, or elbowed aides on at least ten days during the previous month. The incidents occurred while staff members were attempting routine care tasks, including changing her briefs, helping her dress, assisting with bathing, or accompanying her to the bathroom. In response, Vista Grande requested permission to sedate her.
What followed was a bitter, months-long dispute between Tingley's sons and the facility over one of the most divisive issues in long-term care: whether to use antipsychotic drugs to calm agitated dementia patients. The case illustrates the painful choices that families and legal guardians across the country confront when a loved one's behavior becomes difficult to manage.
The medications at the center of such conflicts carry significant risks. The Food and Drug Administration requires drug manufacturers to place warnings stating that these powerful medications raise the risk of death in older adults diagnosed with Alzheimer's disease and related conditions. Despite those dangers, they remain widely prescribed in nursing homes and assisted living facilities.
More than 5 million Medicare beneficiaries carry a dementia diagnosis. A study published in JAMA found that roughly one in four of these patients may be inappropriately prescribed antipsychotics and other brain-altering drugs. These medications can trigger delirium, contribute to falls, and lead to hospitalizations, according to the research.
The federal government has spent 14 years trying to curb the use of psychotropic medications in long-term care settings. Those efforts have nonetheless fallen short of substantially reducing the practice. The persistent gap between policy goals and on-the-ground reality has left families struggling to advocate for alternatives while facilities cite the need to protect residents and staff.
For Tingley's sons, the request to sedate their mother represented a line they did not want crossed. They pushed back against Vista Grande's proposal, setting up a confrontation that would stretch into the new year. The dispute centered not only on Tingley's individual care but also on broader questions about who gets to decide when chemical restraints are appropriate.
Agitation is common among people with dementia, particularly as the disease progresses. Patients may become combative, fearful, or disoriented during personal care, a time when they feel vulnerable and may not understand what is happening. Facilities often face pressure to address such behaviors quickly, and medication can appear to be the most immediate solution.
Yet antipsychotics are not approved to treat dementia-related psychosis or agitation. Their use for these purposes is considered off-label, meaning regulators have not signed off on their safety or effectiveness for this population. The FDA's so-called black box warning, the most serious alert the agency issues, explicitly cautions against using the drugs in older patients with dementia.
Advocates for residents argue that non-drug approaches should be exhausted before medication is considered. Techniques such as redirecting a patient's attention, adjusting the environment, maintaining consistent routines, and training staff in dementia care can reduce agitation without pharmaceutical intervention. These strategies, however, require time, staffing, and specialized training that many facilities lack.
The Tingley case also raises questions about the role of guardians and family members in medical decisions. When relatives disagree with a facility's recommendations, the conflict can become legal, ethical, and deeply personal. Nursing homes may argue that they have a duty to protect all residents and workers, while families may see sedation as a violation of their loved one's dignity and autonomy.
Vista Grande's behavior logs formed the basis of its request to medicate Tingley. The documentation of her physical outbursts underscored the challenges staff faced in delivering daily care. Still, her sons remained unconvinced that drugs were the right answer, preferring to explore other ways to keep their mother and those around her safe.
The standoff reflects a larger national tension. Even as regulators and researchers warn about the harms of antipsychotics, facilities continue to rely on them. The JAMA study's finding that one in four dementia patients on Medicare may be inappropriately prescribed such drugs suggests the problem is systemic rather than isolated to any single institution.
The consequences of overuse extend beyond individual patients. Falls, delirium, and hospitalizations linked to these medications add to the physical and emotional toll on residents and their families. They also drive up health care costs and place additional strain on an already overburdened long-term care system.
Federal campaigns have sought to educate providers and encourage alternatives, but change has been slow. Staffing shortages, high turnover, and limited resources make it difficult for many facilities to implement the labor-intensive, person-centered approaches that experts recommend. In that environment, medication often becomes the default response to challenging behavior.
Marjorie Tingley's story highlights how difficult it can be for families to challenge that default. Her sons wanted to keep her off the drugs, while the facility insisted that sedation was necessary to ensure safety. The resolution of their dispute, and the broader question of how society cares for people with dementia, remains one of the most pressing and unresolved issues in long-term care.
(0)